studies

breast cancer - HER2-positive, EGFR inhibitor vs. non active control, meta-analysis of study results

No data for this selection

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 336,147,145,355,337,146,317 - treatments: 429,903,472,969,902,1321,643,641,640,427,910,430,976,909,966,917,1013,1025,916,977,1029,1017,911,428,971,913,912,918,965,1067,978,915,914,973,974